PTHS (Pelthos Therapeutics) Valuation Rank


PTHS Pelthos Therapeutics Inc PTHS
8 GF Score
Price $29.03
! 5 Warning Signs
View Full Analysis

What is Pelthos Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Pelthos Therapeutics Valuation Rank Related Terms

PTHS
8GF Score
Pelthos Therapeutics Inc PTHS
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pelthos Therapeutics Business Description

Address 4020 Stirrup Creek Drive, Suite 110, Durham, NC, USA, 27703
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
8GF Score

Get the complete analysis for PTHS

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.03
Price